Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Am Heart J. 2020 Jan 21;222:38–45. doi: 10.1016/j.ahj.2020.01.008

Figure II.

Figure II.

Frequency of female sterilization or reversible prescription contraceptive method use overall and by typical effectiveness tier for privately-insured women aged 15–44 years with and without congenital heart defects (CHD), by presence of any CHD and by CHD severity, United States – 2014

Confidence intervals for each estimate are depicted in the interval bars. *Includes female sterilization, intrauterine devices or implants; †Includes depot medroxyprogesterone acetate, oral contraception (combined or progestin-only), patches, or rings. 1.4% of women in the sample utilized a method from both effectiveness tiers in 2014; these women were assigned their highest use tier – Tier I – such that the Tier I and Tier II columns are mutually exclusive.